By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


IsoRay, Inc. 

350 Hills Street
Suite 106
Richland  Washington  99354  U.S.A.
Phone: 509-375-1202 Fax:


Medical Device

Company News
IsoRay (ISR) Announces Preliminary Fourth Quarter F2017 Revenue Of $1.37 Million, 22% Year-Over-Year Increase 8/4/2017 11:04:07 AM
IsoRay (ISR) Announces Appointment Of Mark Austin As Controller, Principal Accounting And Financial Officer 7/7/2017 7:00:38 AM
IsoRay (ISR) Receives FDA Response to 510(k) Application For GammaTile 7/6/2017 6:37:41 AM
IsoRay (ISR) Shows Off Another '100%' Study 6/20/2017 6:39:55 AM
IsoRay (ISR) Announces Third Quarter Fiscal 2017 Financial Results 5/10/2017 11:55:57 AM
IsoRay (ISR) Announces Study Accepted For Publication In The International Journal Of Radiation Oncology, Biology, Physics Entitled "Long-Term Quality Of Life In Prostate Cancer Patients Treated With Cesium-131" 5/3/2017 7:55:12 AM
IsoRay (ISR) Announces Final Court Approval Of Class Action Settlement 3/10/2017 8:06:10 AM
IsoRay (ISR) Announces Second Quarter Fiscal 2017 Financial Results 2/9/2017 9:28:27 AM
IsoRay (ISR) Announces The Launch Of A Pilot Study Using Intraoperative Placement Of Cesium-131 Permanent Interstitial Brachytherapy In Resectable High Risk Recurrent Head And Neck Cancer By Case Comprehensive Cancer Center 12/21/2016 11:56:18 AM
IsoRay (ISR) Announces "Cesium-131 Brachytherapy For Salvage Of Recurrent High Grade Glioma" Poster Presentation At 21st Annual Scientific Meeting Of Society For Neuro-Oncology 11/29/2016 11:33:31 AM